RGMA: Potential Drug Target Or Biomarker (G56963)

Target Name: RGMA

NCBI ID: G56963

RGMA

RGMA: Potential Drug Target Or Biomarker

Repulsive guidance molecule A (RGMA) is a protein that is expressed in various cell types, including neurons, and is known for its role in cell signaling. According to research, RGMA may have potential as a drug target or biomarker.

RGMA is a member of the guidance molecule family, which includes proteins such as cadherin, protocadherin, and E-cadherin. These proteins are known for their ability to interact with cell-cell adhesion molecules and play a role in cell signaling.

One of the key functions of RGMA is its ability to regulate the activity of adenylyl cyclase (AC), an enzyme that is involved in the production of cAMP. CAMP is a well-known molecule that plays a role in various cellular processes, including cell signaling, muscle contractions, and blood pressure.

Research has shown that RGMA can interact with AC and regulate its activity. This interaction between RGMA and AC can have important implications for cell signaling, as AC is involved in the production of a variety of signaling molecules, including cAMP.

In addition to its role in cell signaling, RGMA may also be a drug target or biomarker. For example, some studies have suggested that RGMA may be a potential target for small molecule inhibitors, such as those that can inhibit AC activity.

Another potential mechanism by which RGMA may be targeted by small molecules is its role in cell-cell adhesion. RGMA is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain the integrity of tissues.

Research has shown that RGMA is involved in the regulation of tight junction formation, and that it plays a role in the development of various diseases, including cancer. This suggests that RGMA may be a potential drug target or biomarker for diseases that are characterized by disrupted tight junction formation, such as cancer.

In conclusion, RGMA is a protein that is involved in various cellular processes, including cell signaling and cell-cell adhesion. Its interaction with adenylyl cyclase (AC) suggests that it may be a potential drug target or biomarker for various diseases. Further research is needed to fully understand the role of RGMA in cell signaling and its potential as a drug target or biomarker.

Protein Name: Repulsive Guidance Molecule BMP Co-receptor A

Functions: Member of the repulsive guidance molecule (RGM) family that performs several functions in the developing and adult nervous system. Regulates cephalic neural tube closure, inhibits neurite outgrowth and cortical neuron branching, and the formation of mature synapses. Binding to its receptor NEO1/neogenin induces activation of RHOA-ROCK1/Rho-kinase signaling pathway through UNC5B-ARHGEF12/LARG-PTK2/FAK1 cascade, leading to collapse of the neuronal growth cone and neurite outgrowth inhibition. Furthermore, RGMA binding to NEO1/neogenin leads to HRAS inactivation by influencing HRAS-PTK2/FAK1-AKT1 pathway. It also functions as a bone morphogenetic protein (BMP) coreceptor that may signal through SMAD1, SMAD5, and SMAD8

The "RGMA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RGMA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets